Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 519

1.

Relapsed refractory multiple myeloma: a comprehensive overview.

Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M.

Leukemia. 2019 Oct;33(10):2343-2357. doi: 10.1038/s41375-019-0561-2. Epub 2019 Aug 27. Review.

PMID:
31455853
2.

Current status of autologous stem cell transplantation for multiple myeloma.

Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M.

Blood Cancer J. 2019 Apr 8;9(4):44. doi: 10.1038/s41408-019-0205-9. Review.

3.

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries.

Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, Garcia DK, Vega GQ, Macias J, Oliveros Alvear JW, Royg M, Neves LA, Lopez Dopico JL, Espino G, Ortiz DR, Socarra Z, Fantl D, Ruiz-Arguelles GJ, Maiolino A, Hungria VTM, Harousseau JL, Durie B.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e43-e50. doi: 10.1016/j.clml.2018.08.005. Epub 2018 Aug 29.

PMID:
30297171
4.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

PMID:
30249784
5.

How I treat first relapse of myeloma.

Harousseau JL, Attal M.

Blood. 2017 Aug 24;130(8):963-973. doi: 10.1182/blood-2017-03-726703. Epub 2017 Jul 5. Review.

PMID:
28679737
6.

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

Harousseau JL, Avet-Loiseau H.

J Clin Oncol. 2017 Sep 1;35(25):2863-2865. doi: 10.1200/JCO.2017.73.1331. Epub 2017 May 19. No abstract available.

PMID:
28525304
7.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

8.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
9.

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Malard F, Harousseau JL, Mohty M.

Cancer Treat Rev. 2017 Jan;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. Epub 2016 Nov 15. Review.

PMID:
27888768
10.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14.

11.

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Rajkumar SV, Harousseau JL.

Blood. 2016 Dec 15;128(24):2757-2764. Epub 2016 Oct 14. Review.

12.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.

PMID:
27511158
13.

COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE.

Poullié AI, Cognet M, Gauthier A, Clementz M, Druais S, Späth HM, Perrier L, Scemama O, Pichon CR, Harousseau JL.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):37-45. doi: 10.1017/S0266462316000088. Epub 2016 Mar 9.

PMID:
26956455
14.

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M.

Bone Marrow Transplant. 2016 Feb;51(2):267-72. doi: 10.1038/bmt.2015.250. Epub 2015 Dec 7.

PMID:
26642337
15.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Dejoie T, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.

16.

Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry.

Desplantes C, Fremond ML, Beaupain B, Harousseau JL, Buzyn A, Pellier I, Roques G, Morville P, Paillard C, Bruneau J, Pinson L, Jeziorski E, Vannier JP, Picard C, Bellanger F, Romero N, de Pontual L, Lapillonne H, Lutz P, Chantelot CB, Donadieu J.

Orphanet J Rare Dis. 2014 Dec 10;9:183. doi: 10.1186/s13023-014-0183-8.

17.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.

Brissot E, Cahu X, Guillaume T, Delaunay J, Ayari S, Peterlin P, Le Bourgeois A, Harousseau JL, Milpied N, Bene MC, Moreau P, Mohty M, Chevallier P.

Ann Hematol. 2015 Apr;94(4):663-9. doi: 10.1007/s00277-014-2259-x. Epub 2014 Nov 21.

PMID:
25409914
18.

A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Poullié AI, Gauthier A, Cognet M, Clementz M, Späth HM, Perrier L, Scemama O, Rumeau Pichon C, Harousseau JL.

Value Health. 2014 Nov;17(7):A597. doi: 10.1016/j.jval.2014.08.2062. Epub 2014 Oct 26. No abstract available.

19.

Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Ghabri S, Hamers FF, Josselin JM, Harousseau JL.

Value Health. 2014 Nov;17(7):A441-2. doi: 10.1016/j.jval.2014.08.1160. Epub 2014 Oct 26. No abstract available.

20.

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Rumeau-Pichon C; Health Economics and Public Health Department S, Health Economics and Public Health Committee C, Harousseau JL.

Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.997. Epub 2014 Oct 26. No abstract available.

21.

Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Rumeau-Pichon C; Health Economics and Public Health Department S, Health Economics and Public Health Committee C, Harousseau JL.

Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.996. Epub 2014 Oct 26. No abstract available.

22.

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY.

J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.

23.

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.

Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, Moreau P, Mechinaud F, Milpied N, Mohty M.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1217-23. doi: 10.1016/j.bbmt.2014.04.021. Epub 2014 Apr 23.

24.

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Mohty M, Harousseau JL.

Haematologica. 2014 Mar;99(3):408-16. doi: 10.3324/haematol.2013.096149. Review. No abstract available.

25.

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.

Récher C, Béné MC, Lioure B, Pigneux A, Vey N, Delaunay J, Luquet I, Hunault M, Guyotat D, Bouscary D, Fegueux N, Jourdan E, Lissandre S, Escoffre-Barbe M, Bonmati C, Randriamalala E, Guièze R, Ojeda-Uribe M, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Guardiola P; Groupe Ouest-Est d’ étude des Leucé mies Aiguës et autres.

Leukemia. 2014 Feb;28(2):440-3. doi: 10.1038/leu.2013.290. Epub 2013 Oct 9. No abstract available.

PMID:
24166215
26.

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.

Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau JL, Labussière H, Nicolini FE, Attal M, Moreau P, Mohty M, Blaise D, Avet-Loiseau H.

Exp Hematol. 2013 Dec;41(12):1008-15. doi: 10.1016/j.exphem.2013.08.003. Epub 2013 Aug 29.

PMID:
23994781
27.

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Vey N, Delaunay J, Leymarie V, Luquet I, Blanchet O, Cornillet-Lefebvre P, Hunault M, Bouscary D, Fegueux N, Guardiola P, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Récher C; Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS).

Haematologica. 2014 Jan;99(1):46-53. doi: 10.3324/haematol.2013.091819. Epub 2013 Aug 23.

28.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T.

J Clin Oncol. 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24.

29.

Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.

Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1144-51. doi: 10.1016/j.bbmt.2013.02.003. Epub 2013 Feb 13. Review.

30.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.

J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22.

PMID:
23091109
31.

How to select among available options for the treatment of multiple myeloma.

Harousseau JL.

Ann Oncol. 2012 Sep;23 Suppl 10:x334-8.

PMID:
22987987
32.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

33.

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V, Delaunay J, Chevallier P, Guillaume T, Blin N, Ayari S, Clavert A, Mohty M, Dousset C, Milpied N, Harousseau JL, Moreau P, Wuilleme S, Moreau A, Le Gouill S.

Transplantation. 2012 Aug 15;94(3):295-301.

PMID:
22797728
34.

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Leukemia. 2013 Jan;27(1):202-7. doi: 10.1038/leu.2012.159. Epub 2012 Jun 13.

35.

Proteasome inhibitors in multiple myeloma: 10 years later.

Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL.

Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29. Review.

36.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G.

J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. J Clin Oncol. 2014 Apr 20;32(12):1285.

PMID:
22585692
37.

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators.

N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.

38.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S.

J Clin Oncol. 2012 Jun 1;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649. Epub 2012 Apr 30.

PMID:
22547589
39.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M.

Ann Oncol. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.

PMID:
22440229
40.

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Rousseau C, Ferrer L, Supiot S, Bardiès M, Davodeau F, Faivre-Chauvet A, Baumgartner P, Wijdenes J, Lacombe M, Barbet J, Guillaume T, Moreau P, Harousseau JL, Kraeber-Bodéré F, Cherel M.

Tumour Biol. 2012 Jun;33(3):679-88. doi: 10.1007/s13277-012-0362-y. Epub 2012 Mar 3.

PMID:
22389160
41.

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.

Michallet M, Sobh M, Milpied N, Bay JO, Fürst S, Harousseau JL, Mohty M, Nicolini FE, Labussière H, Tedone N, Morisset S, Vigouroux S, Baumgart J, Tabrizi R, Blaise D.

Ann Hematol. 2012 Aug;91(8):1289-97. doi: 10.1007/s00277-012-1429-y. Epub 2012 Feb 25.

PMID:
22362122
42.

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

Lioure B, Béné MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carré M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY; GOELAMS.

Blood. 2012 Mar 22;119(12):2943-8. doi: 10.1182/blood-2011-05-352989. Epub 2012 Feb 9.

PMID:
22323482
43.

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P.

Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23. Review.

PMID:
22193964
44.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
45.

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.

Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, Bouabdallah K, Alexis Vigier M, Moles MP, Tournilhac O, Arakelyan N, Rodon P, El Yamani A, Sutton L, Fornecker L, Assouline D, Harousseau JL, Maisonneuve H, Caulet-Maugendre S, Gressin R; French GOELAMS group.

Ann Oncol. 2012 Jun;23(6):1555-61. doi: 10.1093/annonc/mdr450. Epub 2011 Oct 19.

PMID:
22012966
46.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

PMID:
21849487
47.

Monoclonal antibodies in the treatment of multiple myeloma.

Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC.

Br J Haematol. 2011 Sep;154(6):745-54. doi: 10.1111/j.1365-2141.2011.08790.x. Epub 2011 Jul 21. Review.

PMID:
21777223
48.

Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities.

Perrot A, Luquet I, Pigneux A, Mugneret F, Delaunay J, Harousseau JL, Barin C, Cahn JY, Guardiola P, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Béné MC, Ifrah N, Witz F; Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang.

Blood. 2011 Jul 21;118(3):679-85. doi: 10.1182/blood-2010-09-307264. Epub 2011 May 26.

PMID:
21622650
49.

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1698-703. doi: 10.1016/j.bbmt.2011.04.010. Epub 2011 May 3.

50.

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

Roussel M, Facon T, Moreau P, Harousseau JL, Attal M.

Recent Results Cancer Res. 2011;183:189-206. doi: 10.1007/978-3-540-85772-3_9. Review.

PMID:
21509686

Supplemental Content

Loading ...
Support Center